Puma Biotechnologyincis A Biopharmaceutical Company Based In Los Angelesfocused On Developing And Commercializing Cancer Therapeuticsfounded In 2010Puma Operates As A Publicly Traded Entity And Has Approximately 265 Employeesthe Company Gained Recognition Through Its Reverse Merger In 2011 And Subsequent Nyse Listing In 2012Reporting $200 1 Million In Revenue In 2019 Puma S Key Product Is Neratinibnerlynxaan Fda Approved Oral Tyrosine Kinase Inhibitor For Her2 Positive Breast Cancerthe Company Is Also Advancing Alisertiban Investigational Drug Currently In Phase Ii Trials For Small Cell Lung Cancer And Hr Positive Her2 Negative Metastatic Breast Cancerpuma Specializes In Strategic In Licensing And Focuses On Drug Development Servicesincluding Clinical Trial Design And Regulatory Strategyparticularly For Niche Oncology Indicationsthe Company Collaborates With Research Institutions And Contract Research Organizations To Enhance Its Clinical Development Efforts
No conferences found for this company.
| Company Name | Puma Biotechnology Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
